Uppsala, Sweden – December 6, 2018 – Orexo AB (publ.), the fully integrated specialty pharmaceutical company addressing opioid addiction and pain, is today hosting the Company’s Capital Markets Day for investors, analysts and media in Stockholm, Sweden.
Orexo’s management team will expand on new strategic initiatives building upon the Company’s strong financial and operational foundation, primarily driven by the performance for Zubsolv® in the US. The event will highlight the Company’s plans to further strengthen its pipeline and innovative formulation technologies. In addition, management will also elaborate on efforts to broaden the commercial platform to leverage scale and expand sales through business development and potentially M&A transactions.
With a highly positive outcome in the recent patent litigation concerning Zubsolv, Orexo’s core asset has received strengthened IP in the US until 2032. The decision has enabled Orexo to continue with its strategy to maximise Zubsolv´s potential in a fast growing US market. The team will also expand on the latest market trends and demonstrate how it intends to further strengthen its market position.
The event will be moderated by Charlotte Stjerngren, former news anchor for Börslunch, where members of the Orexo management team including among others Nikolaj Sørensen, CEO and President, Robert DeLuca, President US Inc., Johannes Doll, EVP and Head of Corporate Development, and Martin Nicklasson, Chairman of the Board of Directors will be presenting. The Keynote speaker is former New Jersey governor, Chris Christie, who will be discussing the current landscape of the opioid crisis, and how to combat it.
All presenters during the Orexo Capital Markets Day
- Martin Nicklasson, Chairman of the Board of Directors, Orexo
- Nikolaj Sørensen, CEO and President, Orexo
- Dan Hawkins, Founder & Managing Director, Clarion Healthcare
- Robert A. DeLuca, President, Orexo US Inc.
- Joseph DeFeo, EVP and Chief Financial Officer, Orexo
- Fred Nyberg, PhD, Professor, Division of Biological Research on Drug Dependence, Uppsala University
- Johannes Doll, EVP and Head of Corporate Development, Orexo
- Michael Sumner, Chief Medical Officer, Orexo
- Robert Rönn, Head of Pharmaceutical Development and IP, Orexo
- Chris Christie, Former Governor of New Jersey and former Chairman of the US President’s Commission on Combating Drug Addiction and the Opioid Crisis
The meeting will be held at the Armémuseet, Riddargatan 13, Stockholm, Sweden. The event will start at 12:00 noon CET with a networking lunch, followed by presentations commencing at
1:00 pm CET.
A live webcast will be available on the Orexo website and questions related to the presentations can also be sent to firstname.lastname@example.org. A replay of the event and presentation slides, excluding Chris Christie´s performance, will be made available shortly after.
For further information, please contact:
Orexo AB (publ.)
Lena Wange, IR and Communications Manager
Tel: +46 (0)18 780 88 00
Consilium Strategic Communications
Mary-Jane Elliott / Jonathan Birt / Olivia Manser / Carina Jurs
Tel: +44 (0)20 3709 5700
Orexo develops improved pharmaceuticals based on innovative drug delivery technologies. The focus is primarily on opioid dependence and pain but the aim is to address therapeutic areas where our competence and technologies can create value. The products are commercialized by Orexo in the US or via selected partners worldwide. The main market today is the American market for buprenorphine/naloxone products, where Orexo sells the product Zubsolv®. Total net sales for 2017 amounted to SEK 643.7 million and the number of employees at year-end was 90. Orexo is listed on the Nasdaq Stockholm Mid Cap (ORX) and is available as ADRs on OTCQX (ORXOY) in the US. The head office, where research and development is also performed, is situated in Uppsala, Sweden.
For more information about Orexo please visit, www.orexo.com. You can also follow Orexo on Twitter, @orexoabpubl, LinkedIn and YouTube.
The information was submitted for publication at 7:30 am CET on December 6, 2018